Results 211 to 220 of about 17,763 (261)
Some of the next articles are maybe not open access.
Pharmacotherapy, 2007
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
exaly +3 more sources
The changing pattern in fungal infections has driven the need to expand the targets of antifungal activity. The echinocandins are the newest addition to the arsenal against fungal infections. Three echinocandins have been approved by the United States Food and Drug Administration: caspofungin, micafungin, and anidulafungin.
Diane, Cappelletty +1 more
exaly +3 more sources
Echinocandins: production and applications
Applied Microbiology and Biotechnology, 2013The first echinocandin-type antimycotic (echinocandin B) was discovered in the 1970s. It was followed by the isolation of more than 20 natural echinocandins. These cyclic lipo-hexapeptides are biosynthesized on non-ribosomal peptide synthase complexes by different ascomycota fungi.
Tamás Emri
exaly +3 more sources
Pediatric Infectious Disease Journal, 2011
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Jill A, Hoffman, Thomas J, Walsh
openaire +4 more sources
The echinocandins (ECs), caspofungin (CA), micafungin (MI), anidulafungin (AD), and aminocandin (AM) are the newest class of parenterally administered antifungal agents. This review will discuss their general properties, current indications, and available pediatric data.
Jill A, Hoffman, Thomas J, Walsh
openaire +4 more sources
Echinocandins in Ocular Therapeutics
Journal of Ocular Pharmacology and Therapeutics, 2017Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections.
Akash, Patil, Soumyajit, Majumdar
openaire +2 more sources
Micafungin - The newest echinocandin
Drugs of Today, 2009Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem, Temesgen +2 more
openaire +2 more sources
Update on Echinocandin Antifungals
Seminars in Respiratory and Critical Care Medicine, 2008Echinocandins are semisynthetic lipopeptides that competitively inhibit an essential cell wall component of Candida and aspergillus. They are generally inactive against other fungi. Resistance to these agents is infrequent to date. Echinocandins exhibit low oral bioavailability and are available only as parenteral formulations that are dosed once daily.
Carol A, Kauffman, Peggy L, Carver
openaire +2 more sources